NCT04901741View on ClinicalTrials.gov

Olaptesed With Pembrolizumab and Nanoliposomal Irinotecan or Gemcitabine/Nab-Paclitaxel in MSS Pancreatic Cancer

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

January 31, 2026

Primary Completion Date

March 31, 2028

Study Completion Date

March 31, 2029

Conditions
Metastatic Pancreatic Cancer
Interventions
DRUG

Olaptesed pegol

400 mg per week as continous infusion until progression or intolerable toxicity

DRUG

Pembrolizumab

200 mg every 3 weeks as i.v. infusion until progression or intolerable toxicity or a maximum of 35 administrations

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

TME Pharma AG

INDUSTRY